Author of

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12442

    +

    P3.06-001 - Serum Nesfatin-1 Level As A Biomarker In Non-Small Cell Lung Cancer (ID 79)

    09:30 - 09:30  |  Author(s): H. Cetinkaya
    • Abstract

    Background
    Nesfatin-1 is an anorexigenic neuropeptide. We have previously reported that serum nesfatin-1 level is decreased in lung cancer patients. In this study, we aimed to investigate possible effects of serum nesfatin-1 level in survival and chemotherapy response of non-small cell lung cancer patients.

    Methods
    Twenty-eight non-small cell lung cancer patients were included in this study. Data were obtained from clinical records and our previously study about nesfatin-1. The patients were divided into two groups according to high nesfatin-1 level or low. Survival data were compared between these groups. Moreover, serum nesfatin-1 levels were investigated in chemotherapy responder and non-responder patients.

    Results
    Three of patients received supportive care alone. Twenty-five patients were treated with platinum-based doublet chemotherapy. In chemotherapy non-responder patients, serum nesfatin-1 level was more lower than in the patients achieved clinical benefit (0.38 ng/ml ±0.12 ng/ml vs 0.55 ng/ml ±0.21 ng/ml; p:0.044). Patients with low nesfatin-1 level had shorter overall survival (OS), but it is not statistically significant (median OS 7.3 months vs 13.8 months, respectively; p: 0.829). Serum nesfatin-1 levels were not also different in between patients survived more than 12 months and not (0.62 ng/ml ±0.22 ng/ml vs 0.46 ng/ml ±0.19 ng/ml; p:0.077).

    Conclusion
    This preliminary study suggests that serum nesfatin-1 level is not prognostic factor in non-small cell lung cancer, but may be a predictive marker for chemotherapy response.